Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

ACADIA Pharmaceuticals

Thumbnail
November 30, 2020

Biogen’s Sage advice amounts to $1.5bn

Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.

Thumbnail
October 20, 2020

Finding the next Vertex

Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.

Article image
Vantage logo
July 21, 2020

No new way for Nuplazid after depression failure

Article image
Vantage logo
June 17, 2020

Neurocrine picks Takeda’s brain

Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.

Article image
Vantage logo
May 04, 2020

Rett failure sets up thin pipeline

Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.

Article image
Vantage logo
February 24, 2020

First fragile X test is approved, and Zynerba could benefit

The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.

Article image
Vantage logo
December 24, 2019

Intra-cellular triples on schizophrenia approval

Article image
Vantage logo
September 09, 2019

Pivotal psychosis study delivers a surprise win for Acadia 

Article image
Vantage logo
July 23, 2019

Nuplazid’s schizophrenia flop provides Advance warning

Acadia has tried to see the positives after a pivotal trial failure with Nuplazid in schizophrenia, but the data bode ill for other label-expansion studies.

Article image
Vantage logo
May 03, 2019

Upcoming events – Acadia hopes for new indications for Nuplazid

Knockout interim data from Acadia’s trials of its antipsychotic in schizophrenia and dementia could make for early approval. But the chances of this are not high.

Article image
Vantage logo
March 21, 2019

No, aducanumab is not an Alzheimer’s drug either

Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Vantage logo
January 19, 2021

The pandemic releases its grip on clinical trials

Vantage logo
January 21, 2021

2020 drug approvals rise despite Covid-19

Vantage logo
January 20, 2021

Glaxo joins the Covid-19 delay queue

Vantage logo
January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.